Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

Thumbnail

USPSTF updates its stance on aspirin use to prevent CVD, sees no benefit for patients 60 or older

These recommendations, the group emphasized, do not include patients with a history of CVD or those who are already taking aspirin for another reason.

fda recall Accupril pfizer

FDA announces another recall of common hypertension medication due to potential cancer risk

The new recall includes five lots of medications distributed from December 2019 to April 2022. Similar products were also recalled back in March for the same reason.

election 2020

Biden-Trump presidential election linked to a higher heart attack risk among white, male and older individuals

“There is a need for awareness of this higher risk of CVD, and further research is warranted to identify strategies that mitigate cardiovascular risk during notable political events,” researchers explained. 

Thumbnail

Mental illness strongly linked with higher CVD mortality

The associations between schizophrenia or bipolar disorder and cardiovascular mortality have grown in recent decades.

Asthma, other allergies linked to a higher risk of high blood pressure, coronary heart disease

The research was presented in South Korea at a two-day event hosted by the American College of Cardiology and Korean Society of Cardiology.

Women who experience infertility may face higher heart failure risk

Researchers examined the health outcomes of 38,528 postmenopausal women—14% of whom had a history of infertility—over a 15-year period. 

FDA announces new insulin recall due to potential labeling issue

The recall is focused on a single batch distributed from December 2021 to March 2022.

Steven Nissen, MD, Cleveland Clinic, explains an ACC.22 late-breaking trials that uses an mRNA drug to greatly reduce lipoprotein A. #ACC22

VIDEO: Use of mRNA drug to lower lipoprotein(a) by up to 98%

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).